Medicina · 2022 · 14 citations · 30 references
MedicineSurgeryUrologyInterventional RadiologyRenal PathologyUltrasonographyContrast-enhanced UltrasonographyContrast-enhanced UltrasoundRenal DiseaseRenal Function TestsRenal Mass EvaluationRenal SurgeryAblation Of Renal MassesContrast EnhancementCryoablation Of Renal TumorsGlomerular Filtration Rate AssessmentLesion Enhancement AssessmentRenal Tumor AblationSmall Renal Mass AssessmentSmall Renal Mass Management
Background and Objectives: To assess efficacy and safety of Percutaneous Cryoablation (PCA) of small renal masses (SRMs) using Trifecta outcomes in a large cohort of patients who were not eligible for surgery. Materials and methods: All PCAs performed in four different centers between September 2009 and September 2019 were retrospectively evaluated. Patients were divided in two different groups depending on masses dimensional criteria: Group-A: diameter ≤ 25 mm and Group-B: diameter > 25 mm. Complications rates were reported and classified according to the Clavien−Dindo system. The estimate glomerular filtration rate (eGFR) was calculated before PCA and during follow-up schedule. Every patient received a Contrast Enhanced Ultrasound (CEUS) evaluation on the first postoperative day. Radiological follow-up was taken at 3, 6, and 12 months for the first year, then yearly. Radiological recurrence was defined as a contrast enhancement persistence and was reported in the study. Finally, Trifecta outcome, which included complications, RFS, and preservation of eGFR class, was calculated for every procedure at a median follow-up of 32 months. Results: The median age of the patients was 74 years. Group-A included 200 procedures while Group-B included 140. Seventy-eight patients were eligible for Trifecta evaluation. Trifecta was achieved in 69.6% of procedures in Group-A, 40.6% in Group-B (p = 0.02). We observed an increased rate of complication in Group-B (13.0% vs. 28.6; p < 0.001). However, 97.5% were <II Clavien−Dindo grade. No differences were found between the two groups regarding eGFR before and after treatment. Further, 24-months RFS rates were respectively 98.0% for Group-A and 92.1% in Group-B, while at 36 months were respectively 94.5% and 87.5% (p = 0.08). Conclusions: PCA seems to be a safe and effective treatment for SRM but in the need of more strict dimensional criteria to achieve a higher possible success rate.
30
Classification of Surgical Complications
Daniel Dindo, Nicolas Demartines, Pierre-Alain Clavien · Annals of Surgery · 2004 · 30.9K citations · Full text
Medicine, Surgery, General Surgery +13
Renal Mass and Localized Renal Cancer: AUA Guideline
Steven C. Campbell, Robert G. Uzzo, Mohamad E. Allaf et al. · The Journal of Urology · 2017 · 1.2K citations · Full text
“Trifecta” in Partial Nephrectomy
Andrew J. Hung, Jie Cai, Matthew N. Simmons et al. · The Journal of Urology · 2012 · 455 citations